About 3F Therapeutics
3F Therapeutics is a company based in Lake Forest (United States) founded in 1998 was acquired by ATS Medical in October 2006. 3F Therapeutics has raised $23.2 million across 3 funding rounds from investors including Boston Scientific, ATS Medical and Domain Associates. 3F Therapeutics operates in a competitive market with competitors including Endologix, Trivascular, Endoron Medical, Shanghai MicroPort Endovascular MedTech and Aptus Endosystems, among others.
- Headquarter Lake Forest, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$23.2 M (USD)
in 3 rounds
-
Latest Funding Round
$6 M (USD), Series C
Apr 25, 2005
-
Investors
Boston Scientific
& 2 more
-
Employee Count
Not available
-
Acquired by
ATS Medical
(Oct 02, 2006)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of 3F Therapeutics
3F Therapeutics has successfully raised a total of $23.2M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $6 million completed in April 2005. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in 3F Therapeutics
3F Therapeutics has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Boston Scientific, ATS Medical and Domain Associates.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life science & tech focused VC firm investing in the US
|
Locked | Locked | Locked | |
|
Wide range of medical devices
|
Locked | Locked | Locked | |
|
Devices for valvular heart disease and arrhythmias are manufactured.
|
Locked | Locked | Locked |
Investor details for 3F Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by 3F Therapeutics
Investment portfolio details for 3F Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - 3F Therapeutics
Detailed financials for 3F Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
3F Therapeutics Comparisons
Peer comparison for 3F Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of 3F Therapeutics
3F Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Endologix, Trivascular, Endoron Medical, Shanghai MicroPort Endovascular MedTech and Aptus Endosystems, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Minimally invasive treatments for aortic disorders are developed and manufactured.
|
|
| Locked | Locked | Locked |
Designs and manufactures for endovascular aortic repair equipment
|
|
| Locked | Locked | Locked |
Endovascular fixation devices for cardiovascular stent grafts are manufactured.
|
|
| Locked | Locked | Locked |
Medical devices for treating aortic diseases are developed.
|
|
| Locked | Locked | Locked |
Endograft anchoring systems for aortic aneurysms are developed.
|
|
| Locked | Locked | Locked |
Endovascular devices for aortic aneurysms are developed.
|
Detailed competitors of 3F Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on 3F Therapeutics
Complete news archive for 3F Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about 3F Therapeutics
3F Therapeutics was founded in 1998 and raised its 1st funding round 5 years after it was founded.
3F Therapeutics is headquartered in Lake Forest, United States. It is registered at Lake Forest, California, United States.
3F Therapeutics is a funded company, having raised a total of $23.2M across 3 funding rounds to date.
3F Therapeutics, a part of Medtronic, is a developer of aortic and mitral valve replacement cardiovascular devices in the United States. The device Aortic Bioprosthesis is a biological replacement aortic heart valve to maintain flow characteristics after implant. The company also developed an invasive and transapical aortic heart replacement technology and devices, including an Enable aortic heart valve, an Entrata aortic valve system, and an Endurance valve system to reduce surgical cross-clamp and cardiopulmonary bypass time utilization for congestive heart failures in patients with right heart failure symptoms, and to replicate the natural mitral apparatus. The company holds more than 130 patents focused on a tubular valve concept which enables minimally invasive surgery to repair or replace heart valves. The company was acquired by ATS Medical in 2006, which was in turn acquired by Medtronic.
3F Therapeutics's top competitors include Endologix, Trivascular and Shanghai MicroPort Endovascular MedTech.
3F Therapeutics has 3 investors. Key investors include Boston Scientific, ATS Medical, and Domain Associates.